Bellingham brothers get experimental gene therapy in attempt to save their sight When 11-year-old Casey Catalan goes on a walk in his Bellingham neighborhood, he hustles to be home before twilight. Once the sun fades, so does Casey's vision, because of a congenital eye disease.
AGTC and Icagen Announce Technology Transfer Agreement June 24, 2010 – AGTC, a privately held company, and Icagen, Inc. (NASDAQ: ICGN) today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies. Icagen is transferring its rights to
AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases Combined Funds and Resources to be used to further demonstrate the AGTC’s AAV system’s ability to deliver sustainable treatments for human retinal diseases.
AGTC Expands its Clinical and Regulatory Expertise with Appointment of Jeffrey Chulay M.D. as Vice President of Chief Medical Officer July 9 2007 - AGTC (Applied Genetic Technologies Corporation), a privately held clinical stage gene therapy company, is pleased to announce that Dr.
AGTC Receives $2 Million Milestone from Genzyme After Successful Transfer of Novel Production Technology June 21, 2007 - AGTC (Applied Genetic Technologies Corporation), a privately held clinical stage gene therapy company, is pleased to announce that it has received a $2 million milestone payment